SummaryRegulatory mechanisms of interleukin-10 (IL10)-producing B cells in mucosal homeostasis are not fully understood. This study shows that IL10-secreting B cells activated by resident bacteria ameliorate T-cell-mediated colitis by inducing T regulatory-1 cells via an IL27-dependent mechanism.Inflammatory bowel diseases (IBD) are chronic, T-cell-mediated intestinal disorders characterized by loss of tolerance to resident enteric bacteria and aggressive inflammatory responses.[@bib1], [@bib2] Regulatory T cells (Treg) have a well-described role in attenuating experimental colitis and IBD. Treg help maintain intestinal homeostasis by preventing inappropriate innate and adaptive immune responses against resident bacteria. CD4^+^ T cells that express forkhead box P3 (Foxp3) and T regulatory-1 (Tr-1) cells that lack Foxp3 expression (Foxp3^neg^), but produce interleukin-10 (IL10) comprise major regulatory T-cell populations in the intestine.[@bib3], [@bib4] CD25^+^Foxp3^+^CD4^+^ Treg prevent colitis in severe combined immunodeficiency mice cotransferred with CD45RB^high^ T cells,[@bib5] and enteric bacterial antigen-specific Tr-1 cells ameliorate colitis induced by pathogenic T helper 1 (T~H~1) cells.[@bib6]

In parallel with Treg cells, B cells contribute to intestinal homeostasis by secreting immunoglobulins that decrease mucosal translocation of luminal bacteria and producing regulatory cytokines that inhibit effector mucosal immune responses.[@bib7] Moreover, antigen presentation by B cells promotes the differentiation of tolerogenic CD4^+^ T cells.[@bib8] B-cell depletion may contribute to the development of human IBD[@bib9] and potentiate murine experimental colitis,[@bib10] suggesting that B cells are protective in IBD. However, the mechanisms by which B cells attenuate intestinal inflammation are not entirely clear.

B cells secrete IL10 as do many other cell types including Treg cells, macrophages, mast cells, epithelial cells, and dendritic cells. IL10 reduces inflammation by inhibiting effector T-cell activation.[@bib11] IL10-deficient (*Il10*^−/−^) and IL10-receptor-deficient mice develop resident enteric bacteria-dependent T~H~1/T~H~17-mediated colitis.[@bib12] The role of IL10 derived from intestinal T-cells and myeloid cells in maintaining mucosal homeostasis is well studied, but relatively little is known about the importance of IL10-producing B cells in IBD and experimental colitis.[@bib9], [@bib10], [@bib13], [@bib14] Moreover, the mechanisms of how IL10-producing B cells potentially maintain mucosal homeostasis in the intestine are poorly understood.

IL27, a member of the IL12 family, consists of Epstein-Barr virus induced gene-3 (EBI3) and p28 subunits and has pleiotropic effects on the immune system. IL27 was originally reported to induce T~H~1 cell development,[@bib15] but it can also suppress the development of T~H~17 cells by decreasing *Rorγt* gene expression and increasing the number of IL10-producing Tr-1 cells but not Foxp3^+^ Treg.[@bib16], [@bib17], [@bib18], [@bib19], [@bib20] IL27 promotes the expansion of Tr-1 cells by up-regulating c-Maf and aryl hydrocarbon receptor in naïve T cells.[@bib20] There is conflicting evidence regarding the role of IL27 in colitis, with some studies showing that IL27 has proinflammatory effects[@bib21], [@bib22], [@bib23] and others demonstrating that IL27 is anti-inflammatory.[@bib24], [@bib25], [@bib26] Thus, IL27 likely plays a pivotal role in regulating the delicate balance between proinflammatory T~H~1/T~H~17 cells and anti-inflammatory IL10-producing T-cell populations in the intestine. However, it is unknown whether IL10-producing mucosal B cells affect the regulatory or proinflammatory functions of IL27.

This study addresses the mechanisms by which IL10-secreting B cells influence regulatory T-cell differentiation and ameliorate T-cell-mediated colitis. We show that IL10-producing B cells suppress wild-type (WT) but not *Il10*^−/−^CD4^+^ T-cell-mediated colitis and are associated with increased frequency of intestinal Tr-1 cells and decreased T~H~1/T~H~17 cytokine profiles. Moreover, we demonstrate that regulatory functions of IL10-secreting B cells are mediated by IL27-signaling in T cells. Together, these findings elucidate novel regulatory mechanisms of IL10-secreting B cells, help explain mechanisms of mucosal homeostasis, and could be exploited to treat IBD.

Materials and Methods {#sec1}
=====================

Mice {#sec1.1}
----

We purchased C57BL/6 (B6).WT, B6.*Il10*^−/−^, B6.*Rag2*^−/−^, and B6.*Il27ra (WSX-1)*^−/−^ mice from Jackson Laboratories (Bar Harbor, ME). We purchased 129S6/SvEv (129).WT mice from Taconic Farms (Germantown, NY). The 129.*Il10*^−/−^ mice were obtained from Dr Donna Rennick (DNAX Laboratories, Palo Alto, CA). The *Il10*^−/−^*Rag2*^−/−^ double-knockout (DKO) mice were generated by crossing B6.*Il10*^−/−^ with B6.*Rag2*^−/−^ mice or 129.*Il10*^−/−^ with 129.*Rag2*^−/−^ mice. The B6.*Il10*^*+/EGFP*^ reporter (Vert-X) mice were obtained from Dr Christopher Karp.[@bib27] These mice were originally maintained in the specific pathogen-free (SPF) facility at the University of North Carolina (UNC), then all 129 strains, B6.WT, *Il10*^−/−^, DKO, and Vert-X mice were derived into germ-free (GF) conditions by embryo transfers, and breeding colonies were established in the GF facility at the UNC. Afterward, the mice were transferred to a SPF room and colonized with SPF feces to maintain SPF colonies. The mice used in this study were born from parents that had also been born and raised in SPF conditions over six generations, and they were used at 8 to 16 weeks of age. These studies were approved by the UNC--Chapel Hill Institutional Animal Care and Use Committee (ACUC) Protocol no. 12--300.0.

Cell Isolation {#sec1.2}
--------------

Mononuclear cells were isolated from the colon lamina propria (LP), mesenteric lymph nodes (MLN), and spleen, as described elsewhere.[@bib13] The MLN were pressed through 70-μm filters into phosphate-buffered saline (PBS) with 2.5% fetal bovine serum (Gibco/Invitrogen, Carlsbad, CA). Spleens were mechanically dissociated, and the red blood cells were lysed with red blood cell lysing buffer (Sigma-Aldrich, St. Louis, MO). For isolation of colonic LP lymphocytes (LPL), the large intestines were washed with cold PBS, opened longitudinally, and cut into 10-mm pieces. Then the intestines were incubated in 1 mM dithiothreitol (Sigma-Aldrich) in Ca^2+^- and Mg^2+^-free Hanks' balanced salt solution (HBSS; Gibco/Invitrogen) for 15 minutes at room temperature. Next, the tissues were incubated in 1 mM EDTA (Sigma-Aldrich) in HBSS for 20 minutes at 37°C with shaking, which was repeated after a thorough washing. The cell suspensions were removed, and the remaining fragments were transferred to flasks containing HBSS with 1 mg/mL of collagenase type 3 (Sigma-Aldrich) and 1% penicillin-streptomycin (Gibco/Invitrogen), then stirred gently for 60 minutes at 37°C. The cell suspensions containing LPL were filtered through a nylon mesh and centrifuged, then the LPL were purified using a 44%--70% discontinuous Percoll gradient (GE Healthcare, Buckinghamshire, UK). After centrifugation at 800*g* for 20 minutes at 22°C, the mononuclear cells were collected from the interface.

Cell Purification {#sec1.3}
-----------------

Splenic B cells were purified magnetically by positive selection with anti-CD19 microbeads after negative selection by a mixture of anti-CD90.2, anti-CD11c, and anti-Ter119 microbeads (Miltenyi Biotec, Auburn, CA) (greater than 99.5% pure and 90% viable). The CD4^+^ T cells were isolated by a CD4^+^ T-cell isolation kit (Miltenyi Biotec) (more than 94.7% pure and 95% viable). In some experiments, unfractionated CD4^+^ T cells were further fractionated into CD25^+^ and CD25^−^ T cells by PE-conjugated anti-CD25 antibody with anti-PE microbeads. Red blood cell lysed-unfractionated splenocytes from *(Il10*^*+/+*^*)Rag2*^−/−^ and DKO mice were used for WT and *Il10*^−/−^ antigen-presenting cells (APC), respectively (more than 88.4% CD11b^+^).

Adoptive Cell Transfer {#sec1.4}
----------------------

The 5 × 10^5^ unfractionated splenic CD4^+^ T cells from 129.WT or *Il10*^−/−^ mice were cotransferred intraperitoneally with or without 1 × 10^6^ B cells from 129.WT or *Il10*^−/−^ mice into 129.DKO mice. The 5 × 10^5^ CD25^−^CD4^+^ T cells from B6.WT, *Il27ra*^−/−^, or Vert-X mice were injected intraperitoneally into B6.DKO mice with or without 1 × 10^6^ B cells from B6.WT or *Il10*^−/−^ donors. The severity of colitis and intestinal cell populations were assessed 3 to 6 weeks after the cell transfer.

Assessment of Colitis {#sec1.5}
---------------------

We evaluated the severity of colitis by blinded histologic scoring, colonic tissue explant cultures, and MLN cell cultures, as described elsewhere.[@bib28]

### Blinded histologic scoring {#sec1.5.1}

Intestinal tissues were removed and fixed in 10% buffered formalin. Histologic inflammation was quantified in paraffin-embedded, H&E-stained sections of cecum, proximal colon, and distal colon in a blinded fashion, with each region being graded from 0 to 4 based on the degree of LP and submucosal mononuclear cellular infiltration, crypt hyperplasia, goblet cell depletion, and architectural distortion. The total histology score represents the summation of the scores for cecum, proximal colon, and distal colon (maximum score 12).

### Colonic tissue explant cultures {#sec1.5.2}

Colonic tissues ware thoroughly washed with cold PBS, shaken at room temperature in RPMI containing 50 μg/mL gentamicin for 30 minutes at 280 rpm, cut into 0.5-cm fragments, and weighed. Colonic tissue fragments were distributed (0.05 g per well) into 24-well plates and incubated in 1 mL of RPMI 1640 medium supplemented with 5% fetal bovine serum, 50 μg/mL gentamicin, and 1% antibiotic/antimycotic (penicillin/streptomycin/amphotericin B; GIBCO, Grand Island, NY) for 20 hours at 37°C. Supernatants were collected and stored at −20°C before use for cytokine quantification.

### Mesenteric lymph node cell cultures {#sec1.5.3}

The 5 × 10^5^ unfractionated MLN cells of individual recipient animals were stimulated in 96-well flat-bottom plates with 10 μg/mL CBL at 37°C, 5% CO~2~ in a humidified incubator. After 72 hours, the culture supernatants were collected for cytokine assays.

Cecal Bacterial Lysate {#sec1.6}
----------------------

Cecal bacterial lysate (CBL) was prepared from the contents of ceca from SPF B6 or 129.WT mice as described elsewhere.[@bib28] The protein concentration of the lysate was determined, and the cells were stimulated with 10 μg/mL of protein. We used B6.CBL and 129.CBL in the culture medium with the cells purified from B6 and 129 mice, respectively.

B Cell, T Cell, and Antigen-Presenting Cell Cultures {#sec1.7}
----------------------------------------------------

The 2.5 × 10^5^ unfractionated CD4^+^ T cells isolated from 129.WT or *Il10*^−/−^ mice were cocultured with 5 × 10^5^ 129.WT or *Il10*^−/−^ B cells along with 2 × 10^5^ 129.*Il10*^−/−^ APC at 200 μL/well (96-well plates) for 72 hours at 37°C with 5% CO~2~. In some experiments, 5 × 10^5^ naïve WT CD25^−^ with or without 2.5 × 10^5^ CD25^+^CD4^+^ T cells from 129.WT or *Il10*^−/−^ mice were cocultured with or without 1 × 10^6^ 129.WT or *Il10*^−/−^ B cells along with 2 × 10^5^ 129.*Il10*^−/−^ APC. In selected experiments, 2.5 × 10^5^ CD25^*−*^CD4^+^ T cells isolated from Vert-X mice, *Il27ra*^−/−^, or (*Il27ra*^*+/+*^) WT mice were cocultured with 5 × 10^5^ B6.WT or *Il10*^−/−^ B cells along with 2 × 10^5^ B6.*Il10*^−/−^ APC. In certain experiments, 2.5 × 10^5^ APC from B6 (*Il10*^*+/+*^) *Rag2*^−/−^ or *Il10*^−/−^*Rag2*^−/−^ mice were cocultured without or with 5 × 10^6^ B cells from B6 WT or *Il10*^−/−^ mice.

In another experiment, 5 × 10^5^ naïve T cells isolated from Vert-X mice and 5 × 10^5^ B6.*Il10*^−/−^ APC were cocultured without or with 1 × 10^6^ B6.WT or *Il10*^−/−^ B cells at 400 μL/well using 48-well transwell plates (0.4-μm pore size) (Costar, Corning, NY). The culture medium was RPMI 1640 (Gibco/Invitrogen) containing 10% fetal bovine serum, 1% penicillin/streptomycin/amphotericin B (Gibco/Invitrogen), and 5 × 10^5^ mol/L 2-mercapt ethanol (Sigma-Aldrich), with 10 μg/mL CBL from either WT 129 or B6 mice or without bacterial lysates.

In selected experiments, 10 μg/mL anti-IL10R neutralizing antibody (BD Biosciences, San Jose, CA), anti-IL27 neutralizing antibody (eBioscience, San Diego, CA), isotype control \[purified rat IgG1 (BD Biosciences) or mouse IgG2a (eBioscience)\], or recombinant murine IL10 or IL27 at 10, 1, or 0.1 ng/mL (PeproTech, Rocky Hill, NJ) was added. After 72 hours, the supernatants were collected for measurement of cytokines by enzyme-linked immunosorbent assay (ELISA), and cells were analyzed by flow cytometry. For bacteria-activated T-cell RNA analysis, CBL-stimulated naïve T cells were reisolated using a CD4^+^ T-cell isolation kit with LD columns (Miltenyi Biotec) 24 hours after coculture with B cells and APC.

Cytokine Measurements {#sec1.8}
---------------------

To evaluate the production of cytokines, ELISAs were performed by the Immunoassay Core of the CGIBD at UNC according to the manufacturer's instructions with the following products: mouse anti-IL10, IL12/23p40, interferon-γ (IFNγ), and IL17 (BD Biosciences), and IL27 (eBioscience). Concentrations of cytokines were established in triplicate culture supernatants by comparison with standard curves generated using the appropriate recombinant cytokine.

Real-Time Polymerase Chain Reaction {#sec1.9}
-----------------------------------

Total RNA was isolated from reisolated CD4^+^ cells using RNeasy Micro Kit (Qiagen, Valencia, CA) and real-time polymerase chain reaction (RT-PCR) was performed as described elsewhere.[@bib28] The primer sequences used in this study are shown in [Table 1](#tbl1){ref-type="table"}.

Flow Cytometry {#sec1.10}
--------------

The antibodies we used in this study were anti-mouse CD4, CD19, CD45, B220, CD3, F4/80, CD11c, CD11b (BD Bioscience), IL10, IL17, IFNγ, IL27p28, and Foxp3 (eBioscience), eBi3 (R&D Systems, Minneapolis, MN), and live/dead cell viability kits (Invitrogen/Life Technologies, Carlsbad, CA). MLN, or colonic LP cells were collected and incubated for 15 minutes at 4°C with anti-CD16/CD32 (BD Bioscience) and then for 20 minutes at 4°C with antibodies for cell surface and live/dead cell viability kits to evaluate the cell phenotype and CD4^+^ T-cell/B-cell reconstitution.

Enumeration of cells expressing IL10, IL17, IFNγ, IL27p28, Ebi3, and Foxp3 was performed by intracellular staining with a fixation and permeabilization solution kit (BD Bioscience) according to the manufacturer's instructions. For intracellular cytokine staining, 100 ng/mL phorbol myristate acetate, 1 μg/mL ionomycin (Sigma-Aldrich), and GolgiStop (BD Biosciences) were added into the medium during the last 4 hours of the culture period. The cells were washed and then analyzed on a CyAn flow cytometer (Beckman Coulter, Brea, CA). Proper isotype antibodies were used as a control, and gated live CD45^+^ cells were analyzed with Summit 5.2 software (Beckman Coulter).

Statistical Analysis {#sec1.11}
--------------------

Statistical analysis was performed using Prism 5 software (GraphPad, San Diego, CA) to compare the mean between two groups with two-tailed, unpaired Student's *t* tests; comparisons of the mean from multiple groups were analyzed with one-way analysis of variance (ANOVA) and the Bonferroni posttest. *P* \< .05 was considered statistically significant.

Results {#sec2}
=======

Interleukin-10-Producing B Cells Attenuate T-Cell-Mediated Colitis via Interleukin-10 Secreting T Cells {#sec2.1}
-------------------------------------------------------------------------------------------------------

To evaluate the role of IL10-producing B cells in regulating colitis in vivo, we cotransferred SPF 129.WT or *Il10*^−/−^CD4^+^ T cells with or without B cells from 129.WT or *Il10*^−/−^ mice into 129.*Rag2*^−/−^*Il10*^−/−^ (DKO) recipients in SPF conditions. The DKO mice that received unfractionated WT CD4^+^ T cells developed moderate T~H~1/T~H~17-mediated colitis by 6 weeks as assessed by histologic scores ([Figure 1](#fig1){ref-type="fig"}*A* and 1*B*) and spontaneous IFNγ and IL17a-secretion by colonic tissue explants ([Figure 1](#fig1){ref-type="fig"}*C*); the cotransferred WT, but not *Il10*^−/−^, B cells suppressed all measured parameters of inflammation. Spontaneous secretion of IL10 in colonic explant cultures was increased in the mice that received WT B cells ([Figure 1](#fig1){ref-type="fig"}*C*). Likewise, CBL-stimulated MLN cells from mice that received WT B cells secreted more IL10 and less IFNγ and IL17a compared with mice that received *Il10*^−/−^ or no B cells ([Figure 1](#fig1){ref-type="fig"}*D*).

We found that the percentages of T and B cells in MLN from mice that received WT B cells were not statistically significantly different compared with the percentages in those that received *Il10*^−/−^ B cells ([Figure 1](#fig1){ref-type="fig"}*E*). The percentages of MLN Foxp3^+^CD4^+^ Treg and *Foxp3* mRNA levels in the distal colon were statistically significantly increased in the mice that received either WT or *Il10*^−/−^ B cells compared with the mice that did not receive B cells ([Figure 1](#fig1){ref-type="fig"}*F*). On the other hand, cotransfer of WT B cells had no effect on histologic inflammation or IFNγ-secretion by colonic tissue explants in mice that received *Il10*^−/−^CD4^+^ T cells even when 10 times more WT B cells were transferred ([Figure 2](#fig2){ref-type="fig"}*A* and *B*), suggesting that IL10-producing B cells inhibit experimental colitis caused by T-cell-transfer only when the T cells are capable of secreting IL10. Moreover, the B cells from the GF and SPF B6.WT mice exhibited similar anti-inflammatory properties ([Figure 3](#fig3){ref-type="fig"}*A* and *B*). Our transferred CD19^+^B220^+^ population that contained mainly naïve B cells, even in SPF mice (more than 95%), received physiologic bacteria stimulation in SPF recipients to stimulate IL10-secretion and regulatory function. On the other hand, B cells from noninflamed GF and inflamed SPF B6.*Il10*^−/−^ mice similarly lacked anti-inflammatory properties in vivo and in vitro, suggesting that the difference in colitis between mice that received WT versus *Il10*^−/−^ B cells is not due to the preexistence of inflammation in the *Il10*^−/−^ donor mice ([Figure 3](#fig3){ref-type="fig"}*A* and *B*).

Physiologically Activated Interleukin-10-Producing B Cells Inhibit Proinflammatory Cytokine-Secretion by T Cells In Vitro {#sec2.2}
-------------------------------------------------------------------------------------------------------------------------

We next sought to determine mechanisms by which IL10-producing B cells inhibit proinflammatory cytokine-secretion by T cells. We measured cytokines in physiological CBL-stimulated cocultures of unfractionated CD4^+^ T and B cells from 129.WT or *Il10*^−/−^ mice and *Il10*^−/−^ APC. We detected increased IL10 in cultures containing WT B cells and the amounts were even higher when cocultured with WT or *Il10*^−/−^ T cells ([Figure 4](#fig4){ref-type="fig"}*A*). In cultures containing WT CD4^+^ cells, the presence of IL10-producing B cells was associated with decreased levels of IFNγ and IL17a compared with cultures that had *Il10*^−/−^ or no B cells ([Figure 4](#fig4){ref-type="fig"}*A* and 4*B*). In contrast, consistent with the inability of WT B cells to attenuate experimental colitis in the absence of IL10-producing T cells, WT B cells were unable to suppress IFNγ and IL17a when cocultured with *Il10*^−/−^ T cells ([Figure 4](#fig4){ref-type="fig"}*A* and *B*). Blockade of IL10-signaling by anti-IL10R antibody increased IFNγ-secretion in the cultures containing WT CD4^+^ T cells, WT B cells, and *Il10*^−/−^ APC, whereas exogenous recombinant-IL10 decreased IFNγ and IL17a-secretion in the cultures containing *Il10*^−/−^CD4^+^ T cells, *Il10*^−/−^ B cells with *Il10*^−/−^ APC. These data indicate that the anti-inflammatory function of IL10-producing B cells may be due in part to their ability to suppress IFNγ and IL17a-secretion and that suppression of IFNγ and IL17 requires the presence of IL10-producing T cells.

Next, we investigated the regulatory function of B cells on T cell subsets. Because CD25^+^CD4^+^ T cells have previously been shown to attenuate chronic T-cell-mediated colitis,[@bib29] we explored whether the regulatory role of IL10-producing B cells was mediated by IL10-secreting CD25^+^CD4^+^ Treg. We measured cytokines in CBL-stimulated cocultures of naïve CD25^−^CD4^+^ T cells from WT mice, CD25^+^CD4^+^ Treg from WT or *Il10*^−/−^ mice, and B cells from WT or *Il10*^−/−^ mice with *Il10*^−/−^ APC. We found that WT B cells produced more IL10 than WT CD25^−^CD4^+^ or CD25^+^CD4^+^ cells alone and that the total amount of IL10 was even higher when cocultured with WT CD25^−^CD4^+^ and/or CD25^+^CD4^+^ T cells ([Figure 4](#fig4){ref-type="fig"}*C*). The majority of IL10-positive cells in the cultures containing WT CD25^−^CD4^+^, WT CD25^+^CD4^+^, and WT B cells were B cells ([Figure 4](#fig4){ref-type="fig"}*D*). The WT but not *Il10*^−/−^ B cells suppressed IFNγ-production by CD25^-^CD4+ T cells to a similar degree as WT or *Il10*^−/−^CD25^+^CD4^+^ Treg cells. CD25^+^CD4^+^ Treg and WT B cells each suppressed IFNγ-secretion, and when added together, the degree of suppression was greater ([Figure 4](#fig4){ref-type="fig"}*C*). On the other hand, the presence of *Il10*^−/−^ B cells enhanced IFNγ-production by both CD25^−^CD4^+^ and CD25^+^CD4^+^ T cells compared with no B cells ([Figure 4](#fig4){ref-type="fig"}*C*). These data suggest that IL10-producing B cells inhibit T~H~1 function to a similar degree as CD25^+^CD4^+^ Treg cells.

Because IL10-producing myeloid cells also regulate effector T cells,[@bib30], [@bib31] we compared the functional capacities of IL10-producing B cells with APC. Interestingly, while WT B cells suppress both IFNγ and IL17, WT APC decreased IFNγ but paradoxically enhanced IL17-secretion despite their IL10-secreting capacity ([Figure 5](#fig5){ref-type="fig"}), suggesting that myeloid WT APC are unable to suppress T~H~17-mediated immune reactions that are regulated by B cells.

Physiologically activated Interleukin-10-Producing B Cells Promote the Differentiation of Naïve CD4^+^ T Cells into Tr-1 cells by Interleukin-10-Dependent Mechanisms {#sec2.3}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

We next determined the influence of IL10-secreting B cells on the development of regulatory T cells in vitro. To investigate this, we quantified induction of Foxp3^+^ or IL10-producing (Foxp3^neg^) Tr-1 cells and T-cell transcripts in CBL-treated B6.*Il10*^−/−^ APC cocultures with CD25^−^CD4^+^ T cells from Vert-X mice (*Il10*^*+/EGFP*^ reporter, IL10-sufficient) and B cells from B6.WT or *Il10*^−/−^ mice. The WT but not *Il10*^−/−^ B cells significantly suppressed differentiation of CD25^−^CD4^+^ T cells into IFNγ^+^ and IL17^+^ cells ([Figure 6](#fig6){ref-type="fig"}*A*). Both WT and *Il10*^−/−^ B cells significantly increased the percentage of Foxp3^+^ T cells ([Figure 6](#fig6){ref-type="fig"}*A*) and *Foxp3* mRNA in reisolated T cells ([Figure 6](#fig6){ref-type="fig"}*B*) consistent with the up-regulation of intestinal Foxp3^+^ T cells in DKO mice that received WT or *Il10*^−/−^ B cells compared with no B cells ([Figure 1](#fig1){ref-type="fig"}*E* and *F*). *Il17a* expression was lower in the presence of either WT or *Il10*^−/−^ B cells whereas *Ifng* expression was decreased only in the presence of WT but not *Il10*^−/−^ B cells ([Figure 6](#fig6){ref-type="fig"}*B*). Of considerable interest, WT but not *Il10*^−/−^ B cells enhanced differentiation of naïve T cells into IL10-producing Tr-1 cells ([Figure 6](#fig6){ref-type="fig"}*A*) and up-regulated *Il10* mRNA expression in reisolated CD4^+^ T cells ([Figure 6](#fig6){ref-type="fig"}*B*). The frequency of Tr-1 cells and IL10-secretion increased and IFNγ and IL17a-secretion decreased in the presence of increasing numbers of WT but not *Il10*^−/−^ B cells ([Figure 6](#fig6){ref-type="fig"}*C*). Together, these data suggest that the regulatory capability of IL10-producing B cells is due in part to their ability to inhibit differentiation of certain effector T-cell subtypes and promote differentiation of discrete regulatory T cell subtypes, including Tr-1 cells.

Whether the observed regulatory features of IL10-producing B cells, including the expansion of Tr-1 cells, was directly due to secreted IL10 or indirectly due to other factors remains unknown. Therefore, we quantified the development of Tr-1 cells in CBL-stimulated cocultures of CD25^−^CD4^+^ T cells from Vert-X mice, *Il10*^−/−^ B cells and *Il10*^−/−^ APC in the presence or absence of exogenous recombinant IL10. Adding increasing amounts of recombinant IL10 significantly decreased IFNγ and IL17a-secretion and increased Tr-1 cells ([Figure 6](#fig6){ref-type="fig"}*D*). These data indicate that B cell secretion of IL10 is capable of down-regulating IFNγ and IL17 and inducing Tr-1 cells.

Next, we wanted to determine whether IL10-producing B cells require physical cell contact with T cells to induce regulatory T cells and suppress inflammation. We cocultured naïve CD4^+^ T cells from Vert-X mice and *Il10*^−/−^ APC with or without B cells from WT or *Il10*^−/−^ mice using transwell plates. Interestingly, WT B cells did not require cell contact with T cells for Tr-1 induction nor suppression of proinflammatory cytokines, indicating that IL10 secretion by B cells confers protection ([Figure 7](#fig7){ref-type="fig"}*A*).

Because IL10-secreting B cells expand Tr-1 cells in vitro, we hypothesized that WT B cells are also associated with increased Tr-1 cells in vivo. To test this, we cotransferred CD25^−^CD4^+^ T cells from Vert-X mice with or without B cells from WT or *Il10*^−/−^ mice into DKO recipients and quantified colonic and MLN Tr-1 cells and Foxp3^+^ Treg. While WT, but not *Il10*^−/−^, B cells significantly induced Tr-1 cells in the colonic LP and MLN, Foxp3^+^ T cells were induced by B cells in an IL10-independent fashion ([Figure 7](#fig7){ref-type="fig"}*B* and *C*). These results suggest that physiologically activated IL10-producing B cells may attenuate colitis by selectively promoting the expansion of immunoregulatory IL10-producing Tr-1 cells in the intestine.

Induction of T Regulatory-1 Cells by Interleukin-10-Secreting B Cells Requires T Cell Interleukin-27 Signaling {#sec2.4}
--------------------------------------------------------------------------------------------------------------

Others have shown that IL27 inhibits differentiation of naïve T cells into T~H~17 cells and promotes the expansion of Tr-1 cells through up-regulating c-Maf and aryl hydrocarbon receptor in naïve T cells.[@bib20] Iwasaki et al[@bib32] demonstrated that IL27-driven Tr-1 induction requires early growth response protein 2 (EGR-2)-mediated B-lymphocyte-induced maturation protein-1 (Blimp-1) induction. Because the presence of IL10-producing B cells in T-cell cocultures is associated with increased gene expression of *Il10*, *Cmaf*, *Ahr*, *Blimp1*, and *Il21* in T cells ([Figure 6](#fig6){ref-type="fig"}*B*), we hypothesized that IL10-secreting B cells increase Tr-1 cells in an IL27-dependent manner. To test this, we cotransferred naïve T cells from WT or *Il27ra*^−/−^ mice with or without B cells from WT or *Il10*^−/−^ mice into B6 DKO mice. Interestingly, the ability of WT B cells to inhibit colitis was abrogated in the absence of IL27-signaling on CD4^+^ T cells ([Figure 8](#fig8){ref-type="fig"}*A*). Spontaneous IFNγ and IL17a-secretion by colonic tissue explants was higher and IL10-secretion was lower in mice that received WT B cells along with *Il27ra*^−/−^CD4^+^ T cells versus WT T cells ([Figure 8](#fig8){ref-type="fig"}*B*). Moreover, WT B cells were unable to induce intestinal Tr-1 cells in the absence of IL27-signaling ([Figure 8](#fig8){ref-type="fig"}*C* and *D*). In vitro, neutralization of IL27 diminished the ability of WT B cells to suppress IFNγ-secretion by T cells and to induce Tr-1 cells ([Figure 9](#fig9){ref-type="fig"}*A*), corresponding with decreased *Ahr* and *Il10-*expression in reisolated T cells ([Figure 9](#fig9){ref-type="fig"}*B*). Moreover, CD25^−^CD4^+^ T cells from *Il27ra*^−/−^ mice were unable to differentiate to Tr-1 cells and produced more IFNγ in the presence of IL10-secreting B cells ([Figure 9](#fig9){ref-type="fig"}*C*). These data suggest that the full ability of IL10-secreting B cells to stimulate Tr-1-development requires IL27-signaling in T cells.

To investigate whether various levels of IL27 were associated with differential Tr-1-induction and anti-inflammatory response by IL10-secreting B cells, naïve B6.WT T cells and *Il10*^−/−^ APC were cocultured with or without B6.WT or *Il10*^−/−^ B cells in the presence or absence of different doses of recombinant IL27. Increasing concentration of recombinant IL27 promoted IFNγ-secretion and decreased IL17a-secretion ([Figure 10](#fig10){ref-type="fig"}), whereas additional recombinant IL27 was not associated with further Tr-1-induction by WT B cells. These data indicate that low to moderate concentrations of IL27 are sufficient for IL10-secreting B cells to induce Tr-1 cells and confer protection whereas excessive IL27 enhances IFNγ-secretion that may exacerbate T~H~1-mediated intestinal inflammation.

Because IL27 is implicated in the development of Tr-1 cells, we sought to identify the cell-type that secretes IL27 in our in vitro coculture system. Although others have previously identified myeloid cells as the primary source of IL27,[@bib15] we detected IL27-secretion by CBL-stimulated B cells, with no difference between *Il10*^−/−^ and WT cells ([Figure 11](#fig11){ref-type="fig"}*A*). We also found markedly higher levels of IL27 with cocultured *Il10*^−/−^ APC and *Il10*^−/−^ B cells, which was abrogated by recombinant IL10. Moreover, the addition of anti-IL10R-blocking antibody to cocultured WT B cells and WT APC enhanced IL27-secretion ([Figure 11](#fig11){ref-type="fig"}*A*). The IL27^+^ B cells, but not the IL27^+^ myeloid cells, were expanded in CBL-stimulated versus nonstimulated cocultures, suggesting that increased IL27 in the cultures containing *Il10*^−/−^ B cells and *Il10*^−/−^ APC was mainly produced by CBL-stimulated *Il10*^−/−^ B cells ([Figure 11](#fig11){ref-type="fig"}*B* and *C*). Together, these data indicate that CBL induces B cells to secrete IL27, especially in the presence of APC and absence of IL10, and that IL10, regardless of the source, controls IL27 secretion.

Discussion {#sec3}
==========

We demonstrate a key role for physiologically stimulated IL10-secreting B cells in mucosal immune homeostasis and provide a mechanism by which resident intestinal microbial components induce IL10-dependent regulatory immune responses that prevent intestinal inflammation. Our in vivo data show that IL10-producing B cells ameliorate T-cell-mediated experimental colitis depending on IL10-production by both cotransferred B cells and CD4^+^ T cells in the absence of IL10-producing APC.

Previous studies of regulatory B cells in experimental colitis have characterized subpopulations of B cells that secrete higher IL10 concentrations. For instance, intestinal CD1d^high^ B cells produce IL10 and attenuate colitis.[@bib10] IL10-secreting splenic B10 cells ameliorate acute DSS-induced colitis,[@bib33] a model that does not require the presence of T cells and microbiota to develop colitis; and peritoneal-derived IL10-producing B cells attenuate colitis in *Il10*^−/−^ mice and when cotransferred with CD45RB^high^ T cells into *Rag2*^−/−^ recipients.[@bib34] However, our unfractionated IL10-producing B cells were sufficient to suppress chronic colitis caused by bacteria-activated WT T cells in an IL10-deficient susceptible host. We found a relatively low percentage of B10 (CD1d^high^CD5^+^) phenotype among the MLN and colonic LP IL10-secreting B cells of recipient mice (data not shown). The anti-inflammatory B cells identified in our study likely have a broader phenotype than the small B10-subset and are most likely physiologically stimulated by resident microbiota in the recipient's intestine to differentiate into resident IL10-secreting B cells or plasma cells that regulate inflammation.

Because several studies have suggested that regulatory B cells modulate inflammation by inducing Foxp3^+^ Treg through glucocorticoid-induced TNFR-related protein (GITR) or transforming growth factor-β (TGF-β),[@bib35], [@bib36] we expected that WT but not *Il10*^−/−^ B cells would attenuate inflammation by inducing intestinal Foxp3^+^ T cells. However, our in vivo and in vitro data show that B cells induce Foxp3^+^ T cells in an IL10-independent fashion as previously indicated,[@bib35] but *Il10*^−/−^ B cells were not fully protective in the absence of IL10-secreting APC. Thus, mechanisms by which WT but not *Il10*^−/−^ B cells suppressed mucosal inflammation required further explanation.

Although cotransferred CD25^+^CD4^+^ Treg can ameliorate T~H~1/T~H~17-mediated colitis induced by naïve CD45RB^high^ T cells transferred into *Rag*^−/−^ mice,[@bib29] our transferred unfractionated WT T cells (containing both naïve and Foxp3^+^CD25^+^CD4^+^ Treg) could not suppress colitis in *Il10*^−/−^*Rag2*^−/−^ mice in the absence of IL10-producing B cells or IL10-secreting APC. Previous studies have implicated a requirement for protective IL10-producing myeloid cells that induce and maintain Foxp3^+^ Treg in T cell transfer colitis models.[@bib28], [@bib37] In our study, WT B cells ameliorated T cell-mediated colitis when cotransferred with WT but not *Il10*^−/−^CD4^+^ T cells, suggesting that IL10-producing B cells can replace IL10-secreting APC in activating protective IL10-producing regulatory CD4^+^ T cells to confer protection. Our in vitro transwell study demonstrated that IL10 secretion by B cells without cell-to-cell contact is sufficient to activate Tr-1 cells and suppress inflammatory cytokine production.

Several studies have demonstrated the capacity of B cells to activate Tr-1 cells. IL10-producing B cells induced Tr-1 cells in a rheumatoid arthritis model,[@bib38] and TLR2-activated B cells regulated *Helicobacter*-induced gastritis by inducing CD25^+^CD4^+^ Tr-1-like cells.[@bib39] These studies addressed the importance of IL10-producing B cells to control effector and regulatory T cells. Therefore, we focused on the key mechanisms by which IL10-producing but not *Il10*^−/−^ B cells induced Tr-1 cells in IBD.

Key findings of our study were that physiologically stimulated IL10-secreting B cells induce mucosal Tr-1 cells in an IL27-signaling-dependent manner and decrease T~H~1/T~H~17 immune responses. The biologic role of IL27 in IBD remains uncertain because IL27 has been implicated as both a proinflammatory and anti-inflammatory cytokine.[@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27] However our data suggest that these pleiotropic protective and inductive effects may be due to different timing or concentrations of IL27 and variable presence of IL10 in the various colitis models. B cells appear to optimally control the regulatory functions of T cells by secreting IL10 with small amounts of IL27, but high concentrations of IL27, particularly in the absence of IL10, enhance IFNγ production.

Because IL10-producing myeloid cells can also induce Tr-1 cells and regulate effector T cells,[@bib30], [@bib31] we compared the functional capacities of IL10-producing B cells with APC and found that WT B cells have a greater ability to induce Tr-1 cells than comparable myeloid APC (data not shown). Of note, although WT B cells suppress both IFNγ and IL17, WT APC decreased IFNγ but paradoxically enhanced IL17-secretion, despite their IL10-secreting capacity. Thus, IL10-secreting B cells appear to be more efficient immunoregulatory cells than myeloid WT APC in that they suppress both T~H~1 and T~H~17-mediated immune reactions. These data indicate that IL10 from several APC sources (myeloid and B cells) activate Tr-1 cells and that IL10-secreting B cells and myeloid cells differentially regulate effector T-cell subsets.

Our in vitro data show that IL10-deficient B cells have pleiotropic effects on CBL-stimulated CD4^+^ T cells, decreasing IL17 while promoting IFNγ production. This effect is consistent with increased IL12p40 production by CBL-stimulated *Il10*^−/−^ B cells versus WT B cells, suggesting that the observed increased IFNγ in the presence of *Il10*^−/−^ B cells is due to higher IL12 secretion by *Il10*^−/−^ B cells. On the other hand, depleting *Il10*^−/−^ B cells by anti-CD20-antibodies worsened mucosal inflammation in *Il10*^−/−^ mice,[@bib35] and bacterial antigen-stimulated *Il10*^−/−^ B cells have some protection against T-cell-mediated colitis,[@bib40] suggesting IL10-independent regulatory mechanisms of B cells. We likewise showed slight protection against colitis by *Il10*^−/−^ B cells and IL10-independent induction of Foxp3^+^ Treg by B cells.

In conclusion, physiologically activated IL10-secreting B cells regulate mucosal inflammation by multiple mechanisms: suppressing effector APC:T cell activity, decreasing proinflammatory cytokine production, and expanding Tr-1 cells in association with immunosuppressive amounts of IL27 ([Figure 12](#fig12){ref-type="fig"}). B cells induce Foxp3^+^ Treg in an IL10-independent manner, but this is not sufficient to maximally protect against colitis. Overall, IL10-secreting B cells have an important role in regulating T-cell function and ameliorating T-cell-mediated colitis. These findings provide new insights into the mechanisms of intestinal immune homeostasis and may provide new targets for IBD therapies.
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![**IL10-secreting B cells ameliorate intestinal inflammation.** The 5 × 10^5^ 129.WT (wild type) unfractionated CD4^+^ T cells were cotransferred with or without 1 × 10^6^ B cells from 129.WT or *Il10*^−/−^ knockout (KO) mice into specific pathogen-free (SPF) 129.*Rag2*^−/−^*Il10*^−/−^ mice. Six weeks later, colonic inflammation was quantified by (*A*) histology (total and segmental scores), photomicrographs (*B*), and cytokine-secretion from unstimulated colon explant cultures (*C*) and from cecal bacterial lysate (CBL)-stimulated mesenteric lymph nodes (MLN) cell cultures (*D*). MLN cells were evaluated for (*E*) the reconstitution of CD4^+^ T cells (CD3^+^CD4^+^) and B cells (CD19^+^B220^+^) and (*F*) the frequency of Foxp3^+^CD4^+^ T-regulatory cells by flow cytometry. mRNA level of *Foxp3* in the distal colon was assessed by real-time polymerase chain reaction. N = 6--7/group, two replicates. Data are presented as mean ± standard error. ∗*P* \< .05; *∗∗P* \< .01; *∗∗∗P* \< .001.](gr1){#fig1}

![**IL10-secreting B cells regulate intestinal inflammation in the presence of T-cell-derived IL10.** 5 × 10^5^ CD4^+^ T cells from SPF 129.WT or *Il10*^−/−^ knockout (KO) mice were cotransferred with or without different numbers of B cells from 129.WT or *Il10*^−/−^ mice into SPF 129.*Rag2*^−/−^*Il10*^−/−^ mice. Six-weeks later, histologic total colon inflammation scores (*A*) and IFNγ-secretion in colon explant cultures (*B*) were measured. N = 6--7/group, two replicates. Data are presented as mean ± SE, ∗*P* \< .05, *∗∗P* \< .01, *∗∗∗P* \< .001 (n = 6--7/group). *N.S*: not statistically significant.](gr2){#fig2}

![**Germ-free (GF) wild-type (WT) B cells have anti-inflammatory properties similar to specific pathogen-free (SPF) WT B cells, but GF *Il10***^**−/−**^**B cells are unable to regulate intestinal inflammation.** (*A*) In vivo, 5 × 10^5^ splenic CD25^-^CD4^+^ T cells from GF B6.WT mice were cotransferred with or without 1 × 10^6^ B cells from GF or SPF B6.WT or *Il10*^−/−^ knockout (KO) mice into SPF B6.*Rag2*^−/−^*Il10*^−/−^ mice. Six weeks after the cell-transfer, the severity of colitis was assessed by total histologic scores and cytokine measurement by colonic tissue explant cultures. N = 6--7/group. Mean ± standard error (SE), ∗*P* \< .05. (*B*) In vitro, 2.5 × 10^5^ splenic CD25^-^CD4^+^ T cells from GF B6.WT mice were cocultured with or without 5 × 10^5^ B cells from B6.WT or *Il10*^−/−^ mice housed in GF or SPF conditions along with 2 × 10^5^ GF *Il10*^−/−^ Antigen-presenting cells 48 hours later, cytokines in the supernatant were measured by enzyme-linked immunosorbent assay (ELISA). N = 6/group, two replicates. Mean ± SE, ∗*P* \< .05; ∗∗*P* \< .01; ∗∗∗*P* \< .001.](gr3){#fig3}

![**Cecal bacteria--stimulated interleukin-10 (IL10)-secreting B cells suppress proinflammatory cytokines to a similar degree as CD25**^**+**^**CD4**^**+**^**T-regulatory cells in vitro.** This protection is eliminated by interleukin-10 (IL10)-signaling blockade. Cytokine secretion was measured in cecal bacterial lysate (CBL)-stimulated cultures containing 2.5 × 10^5^ unfractionated 129.WT or *Il10*^−/−^ KO (knockout) CD4^+^ T cells, 5 × 10^5^ 129.WT (wild type) or *Il10*^−/−^ B cells along with 2.5 × 10^5^ 129.*Il10*^−/−^ antigen-presenting cell (APC) by enzyme-linked immunosorbent assay (ELISA) (*A*) and flow cytometry (*B*). We selectively added 10 μg/mL IL10 receptor (IL10R) antibody or 5 ng/mL recombinant IL10. (N = 6/group, three replicates.) In parallel, IL10 and interferon-γ (IFNγ) were assessed in CBL-stimulated cultures containing WT CD25^-^CD4^+^ T cells, WT or *Il10*^−/−^ B cells, and WT or *Il10*^−/−^CD25^+^CD4^+^ T-regulatory cells (Treg) by ELISA (*C*) (N = 9/group, three replicates). The average numbers of live (live/dead cell staining kit) CBL-stimulated IL10-secreting T and B cells in the cultures containing WT CD25^-^CD4^+^ T cells, WT B cells, and WT CD25^+^CD4^+^ Treg were analyzed by flow cytometry (*D*). Mean ± standard error. ∗*P* \< .05; *∗∗P* \< .01; *∗∗∗P* \< .001.](gr4){#fig4}

![**Interleukin-10 (IL10)-producing B cells have greater ability to suppress IL17a than IL10-producing antigen-presenting cells (APC).** We cocultured 5 × 10^5^ splenic B6.WT (wild-type) CD25^−^CD4^+^ T cells with and without 1 × 10^6^ B cells from B6.WT or *Il10*^−/−^ knockout (KO) mice along with 2 × 10^5^ B6.WT or *Il10*^−/−^ APC. In parallel, 2 × 10^5^ (×1) or 1 × 10^6^ (×5) WT APC were added to the cultures of WT CD25^−^CD4^+^ T cells and *Il10*^−/−^ APC. Cells were stimulated with cecal bacterial lysate for 72 hours and supernatant levels of IL10, interferon-γ (IFNγ) and IL17a were measured by enzyme-linked immunosorbent assay (ELISA). N = 9/group, three replicates; mean ± standard error. ∗*P* \< .05; ∗∗*P* \< .01.](gr5){#fig5}

![**Resident bacteria-activated interleukin-10 (IL10)-producing B cells promote T regulatory-1 (Tr-1) cell-induction and suppress T helper cell T**~**H**~**1/T**~**H**~**17 differentiation of naïve CD4**^**+**^**T cells, in vitro.** (*A*) *Il10*^*EGFP*^ reporter Vert-X CD4^+^ T cells were cocultured with B6.WT (wild type) or *Il10*^−/−^ (knockout) B cells plus B6.*Il10*^−/−^ antigen-presenting cell (APC) with cecal bacterial lysate (CBL) for 72 hours and percentages of IL17^+^, interferon-γ^+^ (IFNγ^+^), Foxp3^+^CD4^+^ T cells, and Tr-1 (IL10^+^, Foxp3^neg^) cells were analyzed by flow cytometry phorbol myristate acetate, ionomycin, and GolgiStop were added in the last 4 hours of cultures. (N = 9/group, three replicates.) (*B*) Transcript levels were evaluated in CD4^+^ T cells that were reisolated after 24 hours of coculture as described in (*A*). (N = 6/group, two replicates.) (*C*) Numbers of Tr-1 cells and cytokine concentrations in supernatants of CBL-stimulated cocultures containing WT CD4^+^ T cells, *Il10*^−/−^ APC and no B cells or increasing numbers of WT or *Il10*^−/−^ B cells are shown. N = 6/group, two replicates. (*D*) Frequency of Tr-1 cells and cytokine concentrations in supernatants of CBL-stimulated cocultures containing WT CD4^+^ T cells, *Il10*^−/−^ B cells and *Il10*^−/−^ APC with or without increasing concentrations of recombinant IL10. N = 6/group, two replicates; data presented as mean ± standard error. ∗*P* \< .05; *∗∗P* \< .01; *∗∗∗P* \< .001.](gr6){#fig6}

![**Interleukin-10 (IL10)-producing B cells do not require physical cell contact with T cells to induce T regulatory-1 (Tr-1) cells and regulate inflammation.** (*A*) 5 × 10^5^ naïve Vert-X CD4^+^ T cells and 5 × 10^5^ B6.*Il10*^−/−^ antigen-presenting cell (APC) (in the lower chamber) were cocultured without or with B6.WT (wild-type) or *Il10*^−/−^ KO (knockout) B cells (either in the upper or lower chamber) with cecal bacterial lysate (CBL) for 72 hours. (N = 5--6/group, two replicates; mean ± SD. ∗*P* \< .05, ∗∗*P* \< .01.) (*B*, *C*) IL10-producing B cells promote Tr-1 cell-induction in vivo. We cotransferred 5 × 10^5^ WT naive Vert-X CD4^+^ T cells with or without 1 × 10^6^ B6. B cells from WT or *Il10*^−/−^(KO) mice into SPF B6.*Rag2*^−/−^*Il10*^−/−^ mice. Three weeks later, the frequency of Tr-1 and Foxp3^+^CD4^+^ T-regulatory cells in mesenteric lymph nodes (MLN) (*B*) and colon lamina propria (LP) (*C*) from *Rag2*^−/−^*Il10*^−/−^ mice were assessed by flow cytometry (CD4^+^ cells gated). N = 8--9/group, two replicates; mean ± standard error. *∗∗P* \< .01; *∗∗∗P* \< .001.](gr7){#fig7}

![**Interleukin-10 (IL10)-producing B cells are unable to attenuate intestinal inflammation in the absence of T cell IL27-signaling, in vivo.** 5 × 10^5^ B6.WT (wild-type) or *Il27ra*^−/−^CD25^-^CD4^+^ T cells were cotransferred with or without 1 × 10^6^ B6. B cells from WT or *Il10*^−/−^ knockout (KO) mice into specific pathogen-free (SPF) B6.*Rag2*^−/−^*Il10*^−/−^ mice. Six weeks later, colonic inflammation was quantified by total histologic score (*A*) and cytokine-secretion from colon explant cultures (*B*). Frequency of T regulatory-1 (Tr-1) and Foxp3^+^CD4^+^ T-regulatory cells in mesenteric lymph nodes (MLN) and colon LP CD4^+^ T cells was assessed by flow cytometry (*C*, *D*). N = 8--9/group, two replicates; mean ± standard error. ∗*P* \< .05; *∗∗P* \< .01.](gr8){#fig8}

![**Blockade of interleukin-27 (IL27) decreases IL10-secreting B-cell-mediated T regulatory-1 (Tr-1) induction in vitro.** (*A*) Frequency of Tr-1 cells and cytokine concentrations in cecal bacterial lysate (CBL)-stimulated cocultures containing 2.5 × 10^5^ B6.WT (wild-type) CD25^-^CD4^+^ T cells, 5 × 10^5^ B6.WT or *Il10*^−/−^ B cells and 2.5 × 10^5^ B6.*Il10*^−/−^ antigen-presenting cells (APC) with the indicated blocking-antibodies (anti-IL27 or isotype control). N = 9/group, three replicates. (*B*) Transcript levels in CD4^+^ T cells that were reisolated after 24 hours from CBL-stimulated cocultures that contained WT CD25^-^CD4^+^ T cells, WT B cells, *Il10*^−/−^ APC, and the indicated blocking antibodies. (N = 6/group, two replicates.) (*C*) Frequency of Tr-1 cells and cytokine levels in CBL-stimulated cocultures containing 2.5 × 10^5^ B6.WT or *Il27ra*^−/−^CD25^−^CD4^+^ T cells, 5 × 10^5^ B6.WT or *Il10*^−/−^ B cells, and 2.5 × 10^5^ B6.*Il10*^−/−^ APC. N = 6/group, two replicates; mean ± standard error. ∗*P* \< .05; *∗∗∗P* \< .001.](gr9){#fig9}

![**Added interleukin-27 (IL27) promotes T helper cell 1 (T**~**H**~**1)-mediated immune responses without affecting wild-type (WT) B cell-induced T regulatory-1 (Tr-1) cells.** 0, 0.1, 1, and 10 ng/mL of recombinant murine IL27 were added to the cecal bacterial lysate (CBL)-stimulated cell cultures containing 2.5 × 10^5^ CD25^−^CD4^+^ T cells from Vert-X mice, 5 × 10^5^ B cells from B6.WT or *Il10*^−/−^ mice plus 5 × 10^5^ B6.*Il10*^−/−^ APC. Tr-1 induction was assessed by flow cytometry and IL10, IFNγ, and IL17a supernatant levels were measured by enzyme-linked immunosorbent assay (ELISA). N = 9/group, three replicates; mean ± standard error. ∗*P* \< .05 (vs no recombinant IL27).](gr10){#fig10}

![**Bacterial lysates induce B cells to produce interleukin-27 (IL27) in the presence of antigen-presenting cell (APC).** (*A*) IL27 concentrations in cecal bacterial lysate (CBL)-stimulated cocultures containing wild-type (WT) or *Il10*^−/−^ knockout (KO) APC and WT or *Il10*^−/−^ B cells, with 10 μg/mL of anti-IL10-receptor or isotype antibodies, or 10 ng/mL of recombinant IL10. (N = 9/group, three replicates; mean ± standard error. *∗∗∗P* \< .001.) Representative figures (*B*) and cell numbers (*C*) for IL27^+^ (p28^+^Ebi3^+^) B cells and CD11b^+^ myeloid cells in CBL-stimulated or nonstimulated cocultures that contains WT B cells with WT APC or *Il10*^−/−^ APC with *Il10*^−/−^ B cells. N = 4/group, two replicates; mean ± standard error.](gr11){#fig11}

![**Proposed regulatory mechanisms of interleukin-10 (IL10)-producing B cells.** Proposed regulatory mechanisms of wild-type (WT) B cells (*A*) compared with *Il10*^−/−^ B cells (*B*) or antigen-presenting cell (APC) and T-cell subsets in the absence of B cells (*C*). B cells regulate mucosal inflammation by multiple mechanisms, including IL10 secretion-dependent 1) direct suppression of APC proinflammatory cytokines, 2) decreasing the proinflammatory cytokines from effector T cells, and 3) stimulating Tr-1 cells in collaboration with low to moderate concentrations of IL27 as well as IL10-independent induction of Foxp3^+^ T-regulatory cells mediated by glucocorticoid-induced TNFR-related protein (GITR) or transforming growth fractor-β (TGF-β). In the absence of IL10 production, B cells produce higher concentrations of IL27 and IL12 p40 and activate T helper cells (T~H~1) to secrete interferon-γ (IFNγ), even though they can include Foxp3^+^ T-regulatory cells (*B*).](gr12){#fig12}

###### 

Polymerase Chain Reaction Primers Used in this Study

  Gene        Sense 5′-3′                   Antisense 5′-3′             Reference
  ----------- ----------------------------- --------------------------- -------------------------
  *Il27p28*   GGCCAGGTGACAGGAGACC           CAGCTTGTACCAGAAGCAAGGG      Collison et al[@bib41]
  *Ebi3*      AGCAGCAGCCTCCTAGCCT           ACGCCTTCCGGAGGGTC           Collison et al[@bib41]
  *Il12a*     TGGCTACTAGAGAGACTTCTTCCACAA   GCACAGGGTCATCATCAAAGAC      Collison et al[@bib41]
  *Il23a*     ATCCAGTGTGAAGATGGTTGTGA       GCAAGCAGAACTGGCTGTTG        Collison et al[@bib41]
  *Il17a*     CTCCAGAAGGCCCTCAGACTAC        AGCTTTCCCTCCGCATTGACACAG    Qu et al[@bib42]
  *Il6*       CCGGAGAGGAGACTTCACAG          TCCACGATTTCCCAGAGAAC        Bao et al[@bib43]
  *Cmaf*      AAATACGAGAAGCTGGTGAGCAA       CGGGAGAGGAAGGGTTGTC         Hiramatsu et al[@bib44]
  *Ahr*       ACATCACCTATGCCAGCCGC          TCTGTGTCGCTTAGAAGGAT        Wurster et al[@bib45]
  *Il21*      AAGATTCCTGAGGATCCGAGAAG       GCATTCGTGAGCGTCTATAGTGTC    Wurster et al[@bib45]
  *Foxp3*     GGCCCTTCTCCAGGACAGA           GCTGATCATGGCTGGGTTGT        Wan and Flavell[@bib46]
  *Rorgt*     TGAGGCCATTCAGTATGTGG          CTTCCATTGCTCCTGCTTTC        Ano et al[@bib47]
  *Tbet*      TTCCCATTCCTGTCCTTCAC          CCACATCCACAAACATCCTG        Ano et al[@bib47]
  *Actb*      AGCCATGTACGTAGCCATCCAG        TGGCGTGAGGGAGAGCATAG        Liu et al[@bib28]
  *Blimp1*    TTCTTGTGTGGTATTGTCGGGACTT     TTGGGGACACTCTTTGGGTAGAGTT   Miyauchi et al[@bib48]
  *Il12b*     CGCAAGAAAGAAAAGATGAAGGAG      TTGCATTGGACTTCGGTAGATG      Made ourselves
  *Ifng*      CTTCCTCATGGCTGTTTCTGG         CGCTTATGTTGTTGCTGATGG       Made ourselves
  *Il10*      GTCATCGATTTCTCCCCTGTG         CCTTGTAGACACCTTGGTCTTGG     Made ourselves
